A double blind, controlled, randomised, clinical study to assess the safety of Repevax administered one month after Revaxis or placebo to healthy adults
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2017
At a glance
- Drugs DT-poliovirus vaccine (Primary) ; DTaP poliovirus vaccine (Primary)
- Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors sanofi pasteur MSD
- 08 Apr 2009 Additional lead trial investigator Anne Fiquet reported by ClinicalTrials.gov.
- 27 Oct 2007 Status changed from in progress to completed.
- 18 Jan 2007 Status changed from recruiting to in progress.